The most plausible hypothesis relates hepatic coma to an abnormality of nitrogen metabolism, wherein ammonia, which is formed in the bowel by the action of urease-containing organisms on dietary protein, is carried to the liver in the portal circulation but fails to be converted into urea because of hepatocellular disease, portal– systemic shunting of blood, or both. As a result, excess NH3 reaches the systemic circulation, where it interferes with cerebral metabolism in a way that is not fully understood. The ammonia theory best explains the basic neuropathologic change. Because the brain is lacking in urea cycle enzymes, Norenberg has proposed that the hypertrophy of the astrocytic cytoplasm and proliferation of mitochondria and endoplasmic reticulum, as well as the increase in the astroglial glutamic dehydrogenase activity, all reflect heightened metabolic activity of these systems within astrocytes associated with ammonia detoxification. Removal of brain ammonia depends on the formation of glutamine, a reaction that is catalyzed by the ATP-dependent enzyme glutamine synthetase, which is compartmentalized to astrocytes. It has been shown in experimental animals that hyperammonemia leads to a depletion of ATP in midbrain reticular nuclei. Whether this is the primary cause of cerebral dysfunction has not been resolved.
Numerous alternative theories have been suggested. One is that CNS function in cirrhotic patients is impaired by phenols or short-chain fatty acids derived from the diet or from bacterial metabolism of carbohydrate. Another theory holds that biogenic amines (e.g., octopamine), which arise in the gut and bypass the liver, act as false neurotransmitters, displacing norepinephrine and dopamine (Fischer and Baldessarini). Zieve has presented evidence that mercaptans (methanethiol, methionine), which are also generated in the gastrointestinal tract and removed by the liver, act in conjunction with NH3 to produce hepatic encephalopathy. This theory and others have been largely discounted; they are the subject of reviews by Butterworth and coworkers, by Zieve, by Rothstein and Herlong, and by Jones and Basile, to which the reader is referred for detailed information.
Also, manganese has emerged as a potential neurotoxin in the pathogenesis of hepatic encephalopathy (Kreiger et al; Pomier-Layrargues et al). In patients with chronic liver disease and with spontaneous or surgically induced portal–systemic shunts, manganese accumulates in the serum and in the brain, more specifically in the pallidum. This accumulation is readily discernible as a pallidal signal hyperintensity on T1-weighted MRI, as mentioned above. Following liver transplantation, there is normalization of these MRI changes and of the associated extrapyramidal symptoms. The effects of manganese chelation on such patients have not been well studied and the mechanisms of accumulated manganese in the pathogenesis of hepatic encephalopathy are not known. It is clear, therefore, that any theory of hepatic encephalopathy must incorporate the cerebral effects of hyperammonemia.